CN1360899A - Dermatitis-treating bezoar medicine and its prepn - Google Patents
Dermatitis-treating bezoar medicine and its prepn Download PDFInfo
- Publication number
- CN1360899A CN1360899A CN 00126785 CN00126785A CN1360899A CN 1360899 A CN1360899 A CN 1360899A CN 00126785 CN00126785 CN 00126785 CN 00126785 A CN00126785 A CN 00126785A CN 1360899 A CN1360899 A CN 1360899A
- Authority
- CN
- China
- Prior art keywords
- parts
- medicine
- bezoar
- treating
- dermatitis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 32
- 206010004542 Bezoar Diseases 0.000 title claims abstract description 11
- 201000004624 Dermatitis Diseases 0.000 title claims abstract description 11
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims abstract description 28
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 26
- 239000000843 powder Substances 0.000 claims abstract description 15
- 229960000583 acetic acid Drugs 0.000 claims abstract description 14
- 239000012362 glacial acetic acid Substances 0.000 claims abstract description 14
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims abstract description 10
- 238000003756 stirring Methods 0.000 claims abstract description 5
- 238000002360 preparation method Methods 0.000 claims description 7
- 239000002253 acid Substances 0.000 claims description 5
- 238000005325 percolation Methods 0.000 claims description 5
- 239000002904 solvent Substances 0.000 claims description 5
- 235000009604 Chrysanthemum X morifolium Nutrition 0.000 claims description 4
- 244000189548 Chrysanthemum x morifolium Species 0.000 claims description 4
- 235000014435 Mentha Nutrition 0.000 claims description 4
- 241001072983 Mentha Species 0.000 claims description 4
- 239000002994 raw material Substances 0.000 claims description 3
- 230000000694 effects Effects 0.000 abstract description 16
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 abstract description 2
- 235000001405 Artemisia annua Nutrition 0.000 abstract description 2
- 240000000011 Artemisia annua Species 0.000 abstract description 2
- 235000016257 Mentha pulegium Nutrition 0.000 abstract description 2
- 244000246386 Mentha pulegium Species 0.000 abstract description 2
- 235000004357 Mentha x piperita Nutrition 0.000 abstract description 2
- 235000008331 Pinus X rigitaeda Nutrition 0.000 abstract description 2
- 241000018646 Pinus brutia Species 0.000 abstract description 2
- 235000011613 Pinus brutia Nutrition 0.000 abstract description 2
- 229940116229 borneol Drugs 0.000 abstract description 2
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 abstract description 2
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 abstract description 2
- 235000001050 hortel pimenta Nutrition 0.000 abstract description 2
- 239000000463 material Substances 0.000 abstract description 2
- 231100000331 toxic Toxicity 0.000 abstract description 2
- 230000002588 toxic effect Effects 0.000 abstract description 2
- 238000004090 dissolution Methods 0.000 abstract 1
- 239000007788 liquid Substances 0.000 abstract 1
- 208000003251 Pruritus Diseases 0.000 description 13
- 238000011282 treatment Methods 0.000 description 11
- 206010040882 skin lesion Diseases 0.000 description 8
- 231100000444 skin lesion Toxicity 0.000 description 8
- 239000008280 blood Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 201000009053 Neurodermatitis Diseases 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000002674 ointment Substances 0.000 description 4
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000007803 itching Effects 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 231100000614 poison Toxicity 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 239000002075 main ingredient Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 238000013077 scoring method Methods 0.000 description 2
- 230000037380 skin damage Effects 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000003860 topical agent Substances 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- KZJWDPNRJALLNS-VPUBHVLGSA-N (-)-beta-Sitosterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]([C@H](CC[C@@H](C(C)C)CC)C)CC4)CC3)CC=2)CC1 KZJWDPNRJALLNS-VPUBHVLGSA-N 0.000 description 1
- CSVWWLUMXNHWSU-UHFFFAOYSA-N (22E)-(24xi)-24-ethyl-5alpha-cholest-22-en-3beta-ol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(CC)C(C)C)C1(C)CC2 CSVWWLUMXNHWSU-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- KLEXDBGYSOIREE-UHFFFAOYSA-N 24xi-n-propylcholesterol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CCC)C(C)C)C1(C)CC2 KLEXDBGYSOIREE-UHFFFAOYSA-N 0.000 description 1
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 description 1
- 206010063409 Acarodermatitis Diseases 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 206010002368 Anger Diseases 0.000 description 1
- 241001161070 Calomela Species 0.000 description 1
- 241000258920 Chilopoda Species 0.000 description 1
- DBAKFASWICGISY-BTJKTKAUSA-N Chlorpheniramine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 DBAKFASWICGISY-BTJKTKAUSA-N 0.000 description 1
- LPZCCMIISIBREI-MTFRKTCUSA-N Citrostadienol Natural products CC=C(CC[C@@H](C)[C@H]1CC[C@H]2C3=CC[C@H]4[C@H](C)[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C LPZCCMIISIBREI-MTFRKTCUSA-N 0.000 description 1
- ARVGMISWLZPBCH-UHFFFAOYSA-N Dehydro-beta-sitosterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)CCC(CC)C(C)C)CCC33)C)C3=CC=C21 ARVGMISWLZPBCH-UHFFFAOYSA-N 0.000 description 1
- 206010048768 Dermatosis Diseases 0.000 description 1
- JKLISIRFYWXLQG-UHFFFAOYSA-N Epioleonolsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4CCC3C21C JKLISIRFYWXLQG-UHFFFAOYSA-N 0.000 description 1
- 241000628997 Flos Species 0.000 description 1
- WJOHZNCJWYWUJD-IUGZLZTKSA-N Fluocinonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)COC(=O)C)[C@@]2(C)C[C@@H]1O WJOHZNCJWYWUJD-IUGZLZTKSA-N 0.000 description 1
- 206010018092 Generalised oedema Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 241000270322 Lepidosauria Species 0.000 description 1
- 206010024229 Leprosy Diseases 0.000 description 1
- 241000124079 Mylabris Species 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- YBRJHZPWOMJYKQ-UHFFFAOYSA-N Oleanolic acid Natural products CC1(C)CC2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C1)C(=O)O YBRJHZPWOMJYKQ-UHFFFAOYSA-N 0.000 description 1
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 description 1
- 241000447727 Scabies Species 0.000 description 1
- 241000239226 Scorpiones Species 0.000 description 1
- 206010040799 Skin atrophy Diseases 0.000 description 1
- 241000271897 Viperidae Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 239000003470 adrenal cortex hormone Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 208000024783 anasarca Diseases 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 230000001857 anti-mycotic effect Effects 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000002543 antimycotic Substances 0.000 description 1
- RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical group [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 description 1
- GXDALQBWZGODGZ-UHFFFAOYSA-N astemizole Chemical class C1=CC(OC)=CC=C1CCN1CCC(NC=2N(C3=CC=CC=C3N=2)CC=2C=CC(F)=CC=2)CC1 GXDALQBWZGODGZ-UHFFFAOYSA-N 0.000 description 1
- MJVXAPPOFPTTCA-UHFFFAOYSA-N beta-Sistosterol Natural products CCC(CCC(C)C1CCC2C3CC=C4C(C)C(O)CCC4(C)C3CCC12C)C(C)C MJVXAPPOFPTTCA-UHFFFAOYSA-N 0.000 description 1
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 1
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 235000013877 carbamide Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 229960003291 chlorphenamine Drugs 0.000 description 1
- 239000003245 coal Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229960001140 cyproheptadine Drugs 0.000 description 1
- JJCFRYNCJDLXIK-UHFFFAOYSA-N cyproheptadine Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2C=CC2=CC=CC=C21 JJCFRYNCJDLXIK-UHFFFAOYSA-N 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000004299 exfoliation Methods 0.000 description 1
- 229960001347 fluocinolone acetonide Drugs 0.000 description 1
- FEBLZLNTKCEFIT-VSXGLTOVSA-N fluocinolone acetonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O FEBLZLNTKCEFIT-VSXGLTOVSA-N 0.000 description 1
- 229960000785 fluocinonide Drugs 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 229940100243 oleanolic acid Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- HZLWUYJLOIAQFC-UHFFFAOYSA-N prosapogenin PS-A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1O HZLWUYJLOIAQFC-UHFFFAOYSA-N 0.000 description 1
- 229910052957 realgar Inorganic materials 0.000 description 1
- 239000003507 refrigerant Substances 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 208000005687 scabies Diseases 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 1
- 229950005143 sitosterol Drugs 0.000 description 1
- NLQLSVXGSXCXFE-UHFFFAOYSA-N sitosterol Natural products CC=C(/CCC(C)C1CC2C3=CCC4C(C)C(O)CCC4(C)C3CCC2(C)C1)C(C)C NLQLSVXGSXCXFE-UHFFFAOYSA-N 0.000 description 1
- 235000015500 sitosterol Nutrition 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 229960005137 succinic acid Drugs 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 238000002562 urinalysis Methods 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Images
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The dermatitis-treating bezoar medicine is prepared with seven kinds of Chinese medicinal materials and through crushing sweet wormwood, pine needle, dark plum and peppermint, percolating the medicine powder with 80-85% concentration ethanol solution to collect percolated liquid; adding glacial acetic acid; grinding borneol and bezoar into fine powder; mixing the fine powder with the said solution while stirring for full dissolution; and adding ethanol solution. The present invention has high curative rate, fast curative effect, and no toxic side effect.
Description
The present invention relates to a kind of treatment dermatosis, particularly treat external application preparation of neurodermatitis and preparation method thereof.
At present the Chinese and western drugs of treatment neurodermatitis is few, and curative effect is not as people's will, the medicine that doctor trained in Western medicine adopts, though some short term effects are arranged, relapse rate is very high, and late result is poor; As this sick antihistaminic class medicine that adopts for oral administration of external western medical treatment, as Cyproheptadine, chlorphenamine, this class of hismanal, external corticosteroid hormone class medicine, as carbamide ointment, fluocinonide ointment, dexamethasone ointment etc., bring into use curative effect obvious, but very fast recurrence, even knock-on deterioration phenomenon appears.For a long time with side effect such as atrophoderma wrinkle even anasarca, hypertension, diabetes, acne occurring.The domestic traditional Chinese medical science adopts that then heat-clearing and toxic substances removing for oral administration, dispelling wind for relieving itching, removing heat from blood are moisturized etc. Chinese medicine, but the many difficult through sick institutes of oral medicine, it is slow to take effect.And external used medicine mostly is Arsenicum sablimatum, Mylabris, Calomelas, Realgar, Venenum Bufonis, Semen Strychni, Flos Rhododendri Mollis, Herba Droserae Lunatae, five poisonous creatures: scorpion, viper, centipede, house lizard, toad wine and so on composition, and toxic and side effects is bigger, and how undesirable curative effect is.
Purpose of the present invention aims to provide a kind of topical agent dermatitis-treating bezoar medicine low than high curative rate, instant effect, relapse rate, the more satisfactory healing neurodermatitis that has no side effect that has.
Another object of the present invention provides the preparation method of this topical agent dermatitis-treating bezoar medicine.
The objective of the invention is to realize that by following manner medicine of the present invention is made by following component: Calculus Bovis, Herba Artemisiae Annuae, Folium Pini, Fructus Mume, Herba Menthae, Borneolum Syntheticum, glacial acetic acid.By weight, wherein 0.1～1.5 part of Calculus Bovis, 40～60 parts of Herba Artemisiae Annuaes, 45～60 parts of Folium Pinis, 45～60 parts of Fructus Mumes, 45～70 parts of Herba Menthaes, 4～5.5 parts of Borneolum Syntheticums, 90～120 parts in glacial acetic acid.
Preferred weight (part) ratio range for preparing medicine of the present invention is: 0.5～1.2 part of Calculus Bovis, 50～55 parts of Herba Artemisiae Annuaes, 50～55 parts of Folium Pinis, 50～55 parts of Fructus Mumes, 50～60 parts of Herba Menthaes, 4.2～5.2 parts of Borneolum Syntheticums, 100～110 parts in glacial acetic acid.
Compound method of the present invention is: by said ratio (weight is in gram), get Herba Artemisiae Annuae, Folium Pini, Fructus Mume, Herba Menthae powder and be broken into coarse powder, the ethanol with 80～85% is solvent, carries out percolation by 3ml/min speed, collect the about 700～900ml of percolate, add glacial acetic acid acid and shake up; Other gets Borneolum Syntheticum, Calculus Bovis and is ground into fine powder respectively, joins in the above-mentioned solution, fully stirs, dissolves, filters, and the ethanol of interpolation 75% is to 1000ml.
Accompanying drawing is a process chart of the present invention.
Cow-bezoar of the present invention has heat-clearing and toxin-vanquishing, cooling blood, expelling wind, the kind characteristics of controlling all sore swollen toxins, is main ingredient of the present invention. The dark plum Main Ingredients and Appearance is that citric acid (19%) and malic acid (15 %) also contain butanedioic acid, carbohydrate, sitosterol, ceroidlike material and oleanolic acid sample material. Pharmacological research confirms that dark plum has antimycotic and anti-allergic effects. Pine needle has dispellings wind and arresting itching, the kind effect of controlling stubborn dermatitis scabies leprosy. Sweet wormwood, peppermint then have the effect of being apt to into liver and gall, removing heat from the liver, loose stagnated fire, walk to alter and borneol is refrigerant, and skin moistening and itch stopping is that hundred medicines are first, and dark plum and light-coloured vinegar all have acid convergence sore itching-relieving efficacies, and glacial acetic acid also has as molten coal, concocts all medicines. Because medicament of the present invention has the heat-clearing poison, changes irascibility, the profit skin, relieving itching, hold back the effect of stubborn dermatitis. The present invention has the cure rate height by clinical practice, instant effect, the characteristics that recurrence rate is low.
For showing medicament of the present invention to the result for the treatment of of neurodermatitis, the present invention is through 60 routine clinical observations, and selects two groups to use PIYANNING DINGs and each 30 example of fluocinolone acetonide ointment, as two groups of paired observations of B, C. A group 60 examples are for using medicament of the present invention. More than all make liver function and blood before and after the 120 routine patient treatments, routine urinalysis detects, every normal person includes treatment target in. Whether observe medicine after treatment finishes exerts an influence. 3 groups of sexes, age, the course of disease and medicine typing situations (seeing Table 1)
Sex, age, the course of disease and the medicine typing of table 1:3 group be (X+S) relatively
Annotate: Analysis of variance, 3 groups of sexes, age, the course of disease and medicine typing no significant differences.
| Group (n) | Sex (n) | Age | The course of disease | Medicine typing | |
| Liver depression deficiency of blood wind | |||||
| Fire (n) | Dry (n) | ||||
| A 60 | Man 32 | 36.4+16.4 | 5.6+6.8 | 12 | 20 |
| Woman 28 | 13 | 15 | |||
| B 30 | Man 15 | 38.1-17.2 | 6.7+10.1 | 8 | 7 |
| Woman 15 | 10 | 5 | |||
| C 30 | Man 18 | 41.3+17.9 | 6.7+7.8 | 8 | 10 |
| Woman 12 | 7 | 5 | |||
Observation of curative effect
Criterion of therapeutical effect is formulated with reference to " Chinese traditional medical diagnose standard ". Cure: skin undermines that symptom all disappears or residual pigmentation or pigment disappear; Take a turn for the better: attenuation before skin decreases, exfoliation reduces. Conscious itch alleviates or the skin damage disappears more than 30%; Invalid: the skin damage remains unchanged or disappears less than 30%. Subjective symptoms is without obvious improvement.
Skin lesion scoring method (1) skin lesion areameter point-score before controlling: area 100cm
2More than meter is 1 minute, 31～99cm
2More than meter is 2 minutes; 30cm
2Below meter is 3 minutes; No skin lesion meter 4 minutes.(2) skin crust thickness point system: plump meter 1 minute, thicker meter 2 minutes, thin meter 3 minutes, no crust meter 4 minutes.(3) pruritus degree point system: severe meter 1 minute, moderate meter 2 minutes was slightly counted 3 fens, no pruritus meter 4 minutes.
Control back skin lesion scoring method (1) skin lesion areameter point-score: the skin lesion area does not have to dwindle or enlarge to be counted 1 fen, and the skin lesion area dwindles more than 31% to be counted 3 fens.No skin lesion meter 4 minutes.(2) skin crust thickness point system: skin crust thickness no change or thicken the meter 1 minute, the more preceding attenuate of skin crust was counted 2 fens below 30%, the more preceding attenuate of skin crust was counted 3 fens more than 31%, no crust meter 4 minutes.(3) pruritus degree point system: pruritus does not alleviate or added restatement 1 minute, and pruritus alleviated meter below 50% 2 minutes, and pruritus alleviates more than 50% counted no pruritus meter 4 minutes 3 fens.
Observe in the 7th, 14,20 day 3 times of treatment.The recurrence situation then was respectively 3 months, 6 months and 1 year 3 months points carry out tracing study.
Therapeutic outcome (seeing Table 2,3,4)
The total mark difference compares (d+Sd branch) before and after the treatment of table 2:3 group erythra
| Group | ????n | Treated 7 days | Treated 14 days | Treated 20 days |
| ????A | ????60 | ??2.33+0.75 | ??4.30+1.12 | ??6.25+1.70 |
| ????B | ????30 | ??1.00+0.95 | ??1.67+1.58 | ??2.60+2.27 |
| ????C | ????30 | ??1.30+0.65 | ??2.63+1.00 | ??4.10+2.00 |
Annotate: treating 7 days F values is 35.23, and treating 14 days F values is 50.86, and treating 30 days F values is 38.38; More equal P＜0.01 between 3 months section groups.
Table 3:3 group therapeutic outcome is (example) relatively
| Group | Cure | Take a turn for the better | Do not heal | Add up to | Effective percentage (%) |
| ????A | ????40 | ????18 | ????2 | ????60 | ????96.7 |
| ????B | ????10 | ????10 | ????10 | ????30 | ????66.7 |
| ????C | ????15 | ????10 | ????5 | ????30 | ????83.3 |
Annotate: analyze X through Ridit
2=11.03, P＜0.005 shows 3 groups of effective percentage differences highly significants, with A group curative effect the best.
Table 4:3 group recurrence situation (example)
| Group | Recurrence in March | Recurrence in June | Recurrence in 1 year | Not recurrence | Add up to | Relapse rate (%) |
| ??A | ????1 | ????1 | ????2 | ????54 | ??58 | ????66.9 |
| ??B | ????2 | ????2 | ????2 | ????14 | ??20 | ????30.0 |
| ??C | ????10 | ????1 | ????1 | ????13 | ??25 | ????48.0 |
Annotate: analyze X through Ridit
2=10, P＜=0.005 shows 3 groups of relapse rate differences highly significants, is minimum with the A relapse rate wherein, and C group relapse rate in 3 months is the highest.
Three groups obvious adverse reaction all do not occur in the treatment.After the treatment, liver function and blood, routine urianlysis are all no abnormal.
Embodiment 1:
Take by weighing raw material (gram) Calculus Bovis 1.0, Herba Artemisiae Annuae 40, Folium Pini 55, Fructus Mume 45, Herba Menthae 50, Borneolum Syntheticum 4, glacial acetic acid 95, a certain amount of 75% ethanol by following proportioning.Get Herba Artemisiae Annuae, Folium Pini, Fructus Mume, Herba Menthae powder and be broken into coarse powder, the ethanol with 81% is solvent, carries out percolation by 3ml/min speed, collects the about 800ml of percolate, and the acid of adding glacial acetic acid shakes up; Other gets Borneolum Syntheticum, Calculus Bovis and is ground into fine powder respectively, joins in the above-mentioned solution, fully stirs, dissolves, filters, and the ethanol of interpolation 75% is to 1000ml.
Embodiment 2:
Take by weighing raw material (gram) Calculus Bovis 1.5, Herba Artemisiae Annuae 55, Folium Pini 50, Fructus Mume 50, Herba Menthae 60, Borneolum Syntheticum 5.5, glacial acetic acid 100, a certain amount of 75% ethanol by following proportioning.Get Herba Artemisiae Annuae, Folium Pini, Fructus Mume, Herba Menthae powder and be broken into coarse powder, the ethanol with 83% is solvent, carries out percolation by 3ml/min speed, collects the about 800ml of percolate, and the acid of adding glacial acetic acid shakes up; Other gets Borneolum Syntheticum, Calculus Bovis and is ground into fine powder respectively, joins in the above-mentioned solution, fully stirs, dissolves, filters, and the ethanol of interpolation 75% is to 1000ml.
Claims (4)
1, dermatitis-treating bezoar medicine; the medicine of its raw material is made by following component: Calculus Bovis, Herba Artemisiae Annuae, Folium Pini, Fructus Mume, Herba Menthae, Borneolum Syntheticum, glacial acetic acid; by weight, wherein 0.1～1.5 part of Calculus Bovis, 40～60 parts of Herba Artemisiae Annuaes, 45～60 parts of Folium Pinis, 45～60 parts of Fructus Mumes, 45～70 parts of Herba Menthaes, 4～5.5 parts of Borneolum Syntheticums, 90～120 parts in glacial acetic acid.
2, according to the described dermatitis-treating bezoar medicine of claim 1, preferred weight (part) ratio range of preparation medicine of the present invention is: 0.5～1.2 part of Calculus Bovis, 50～55 parts of Herba Artemisiae Annuaes, 50～55 parts of Folium Pinis, 50～55 parts of Fructus Mumes, 50～60 parts of Herba Menthaes, 4.2～5.2 parts of Borneolum Syntheticums, 100～110 parts in glacial acetic acid.
3, the preparation method of dermatitis-treating bezoar medicine is characterized in that (weight is in gram), gets Herba Artemisiae Annuae, Folium Pini, Fructus Mume, Herba Menthae powder and is broken into coarse powder, ethanol with 80～85% is solvent, carry out percolation by 3ml/min speed, collect the about 700～900ml of percolate, add glacial acetic acid acid and shake up; Other gets Borneolum Syntheticum, Calculus Bovis and is ground into fine powder respectively, joins in the above-mentioned solution, fully stirs, dissolves, filters, and the ethanol of interpolation 75% is to 1000ml.
4,, it is characterized in that desirable 83% ethanol is that solvent carries out percolation according to the preparation method of the described dermatitis-treating bezoar medicine of claim 1.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 00126785 CN1360899A (en) | 2000-12-29 | 2000-12-29 | Dermatitis-treating bezoar medicine and its prepn |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 00126785 CN1360899A (en) | 2000-12-29 | 2000-12-29 | Dermatitis-treating bezoar medicine and its prepn |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1360899A true CN1360899A (en) | 2002-07-31 |
Family
ID=4592068
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 00126785 Pending CN1360899A (en) | 2000-12-29 | 2000-12-29 | Dermatitis-treating bezoar medicine and its prepn |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1360899A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7357950B2 (en) | 2003-03-21 | 2008-04-15 | Elizabeth Anne Mazzio | Topical treatment for dyshidrosis (pompholyx) and dry skin disorders |
| US7666451B2 (en) | 2003-03-21 | 2010-02-23 | Elizabeth Anne Mazzio | Method of treating dyshidrosis(pompholyx) and related dry skin disorders |
-
2000
- 2000-12-29 CN CN 00126785 patent/CN1360899A/en active Pending
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7357950B2 (en) | 2003-03-21 | 2008-04-15 | Elizabeth Anne Mazzio | Topical treatment for dyshidrosis (pompholyx) and dry skin disorders |
| US7666451B2 (en) | 2003-03-21 | 2010-02-23 | Elizabeth Anne Mazzio | Method of treating dyshidrosis(pompholyx) and related dry skin disorders |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103340965B (en) | External pharmaceutical composition used for treating skin diseases like eczema, dermatitis and tinea and preparation method thereof | |
| CN107260612B (en) | Chloasma removing composition, application, compound preparation and preparation method | |
| CN113813224A (en) | Novel azelaic acid gel and preparation method thereof | |
| CN1360899A (en) | Dermatitis-treating bezoar medicine and its prepn | |
| CN101143166B (en) | Medicine for swelling and relieving pain and its preparation method and application | |
| CN117797086A (en) | An anti-inflammatory and anti-acne medicinal gel and its preparation method | |
| CN104706919B (en) | A kind of pharmaceutical composition for the treatment of ulcer in body surface | |
| CN101940652B (en) | Chinese medicinal liniment for treating psoriasis, multiple kinds of stubborn dermatitis and pruritus | |
| CN108524811A (en) | Reduce uric acid, cholesterol, three high Chinese medicine compositions and its preparation method for the treatment of | |
| CN110812377B (en) | Acne treatment and repair composition and application thereof | |
| CN106880654B (en) | Application of panax japonicus extract in preparing medicine for treating rhinitis and composition | |
| CN107823124A (en) | A kind of Olopatadine hydrochloride topical composition and its cream | |
| CN106728168A (en) | A kind of traditional Chinese medicine for external application for treating eczema, psoriasis and preparation method thereof | |
| CN105832657B (en) | A kind of compound lactic acid emulsifiable paste, preparation method and application | |
| CN119385914B (en) | Preparation method for promoting transdermal absorption of external application medicine, external application medicine composition and application thereof | |
| CN103735974B (en) | A kind of care drug of preventing the rear discomfort of operative incision healing | |
| CN1526424A (en) | Swelling eliminating and pain relieving plaster | |
| CN109395050A (en) | Paediatrics external application massage the ointment formula, preparation method and application for treating diarrhea | |
| CN101584746B (en) | Pharmaceutical composition for wound healing and preparation method thereof | |
| CN102406790A (en) | A Chinese medicinal capsule for treating mammary gland hyperplasia, and its preparation method | |
| CN111000902B (en) | Traditional Chinese medicine tincture for treating acute soft tissue injury and preparation method thereof | |
| CN118319923A (en) | Application of Chinese prickly ash triterpene in preparation of medicine for treating skin pressure injury | |
| CN101708240B (en) | Heard-brain benefiting dropping pills and method for preparing same | |
| CN1259921C (en) | New medicine for treating beriberi | |
| CN105833020A (en) | External-use nursing medicinal composition capable of promoting postoperative wound healing |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |